2023 NOV 20 (NewsRx) — By a
“OBJECTIVE: To study the association of NDMA-contaminated generic valsartan with cancer incidence. DESIGN: Nationwide longitudinal observational cohort study. SETTING: Claims data from the
“RESULTS: Among participants (mean [standard deviation] age 59.5 [13.1] years; male, 53.5%), new users had adjusted hazard ratios and 95% confidence intervals (CI) of 1.069 (1.054 to 1.085) and 1.142 (1.100 to 1.186) for any cancer in the NDMA-exposed period (versus NDMA-unexposed) before and after 1:1:1 PSM, respectively. Regardless of PSM, lung and prostate cancer risks increased significantly during the NDMA-exposed period whereas, post-PSM, cancer risk did not increase in the eventually-NDMA-uncontaminated group, even in new users. All-cause and cardiovascular mortality did not differ significantly with NDMA exposure before and after emergent banning.
“CONCLUSIONS: NDMA-contaminated valsartan increased cancer risk, especially of lung and prostate cancers. All-cause and cardiovascular mortality did not evidently increase following banning.
“This supports emergent health-policy action against potentially carcinogenic drugs.”
This preprint has not been peer-reviewed.
For more information on this research see: http://medrxiv.org/content/10.1101/2023.11.01.23297897v1
(Our reports deliver fact-based news of research and discoveries from around the world.)
The post The Medical Impact of Emergent Banning of N-nitrosodimethylamine (NDMA)- contaminated Antihypertensive Drug: A nationwide longitudinal cohort study: Oncology – Prostate Cancer appeared first on Insurance News | InsuranceNewsNet.